Skip to main content
ACRV
NASDAQ Life Sciences

Wiseek Filing Insight

Analysis by Wiseek.ai
Sentiment info
Neutral
Importance info
4
Price
$1.818
Mkt Cap
$70.127M
52W Low
$1.05
52W High
$3.56
Market data snapshot near publication time

check_boxKey Events

  • No key events were highlighted for this filing.

auto_awesomeAnalysis

No analysis available.

At the time of this filing, ACRV was trading at $1.82 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $70.1M. The 52-week trading range was $1.05 to $3.56. This filing was assessed with an importance score of 4 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed ACRV - Latest Insights

ACRV
Apr 23, 2026, 4:29 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
RA Capital Management Increases Stake in Acrivon Therapeutics with $7M ATM Offering Purchase
Sentiment: Positive
View Wiseek Article
ACRV
Apr 17, 2026, 4:00 PM EDT
Source: GlobeNewswire
Importance Score:
7
Acrivon's ACR-368 & ACR-2316 Show Strong Synergies with Checkpoint Inhibitors, ADCs at AACR, Expanding Clinical Paths
Sentiment: Positive
View Wiseek Article
ACRV
Mar 19, 2026, 7:10 AM EDT
Filing Type: 10-K
Importance Score:
8
Acrivon Reports Strong Clinical Data for ACR-368 & ACR-2316, Secures Breakthrough Device Designation, and Extends Cash Runway
Sentiment: Positive
View Wiseek Article
ACRV
Mar 17, 2026, 5:54 PM EDT
Source: GlobeNewswire
Importance Score:
8
ACR-2316 Achieves Complete Tumor Regression in Preclinical Combo, ACR-368 Shows ADC Synergy
Sentiment: Positive
View Wiseek Article
ACRV
Mar 03, 2026, 3:03 PM EST
Source: Wiseek News
Importance Score:
8
Acrivon Therapeutics Expands Global ACR-368 Trials Following Strong Efficacy Data
Sentiment: Positive
View Wiseek Article
ACRV
Mar 02, 2026, 4:30 PM EST
Filing Type: 8-K
Importance Score:
7
Acrivon Therapeutics Takes Full Control of ACR-368 Diagnostic Development In-House
Sentiment: Positive
View Wiseek Article
ACRV
Jan 16, 2026, 4:02 PM EST
Filing Type: 4
Importance Score:
7
Acrivon Therapeutics CEO Buys $82K in Stock, Signaling Confidence
Sentiment: Positive
View Wiseek Article
ACRV
Jan 08, 2026, 9:00 AM EST
Filing Type: 8-K
Importance Score:
9
Acrivon Therapeutics Reports Strong Clinical Data for ACR-368 in Endometrial Cancer and Promising ACR-2316 Phase 1 Results
Sentiment: Positive
View Wiseek Article
ACRV
Jan 08, 2026, 7:30 AM EST
Filing Type: 8-K
Importance Score:
9
Acrivon Therapeutics Reports Strong Cash Position and Positive Clinical Data Across Multiple Programs
Sentiment: Positive
View Wiseek Article